Text Size

Pulmonary Hypertension Institutional Registry (RIHP)

This study is currently recruiting participants.
Verified December 2011 by Hospital Italiano de Buenos Aires
Sponsor:
Information provided by (Responsible Party):
Diego Giunta, Hospital Italiano de Buenos Aires
ClinicalTrials.gov Identifier:
NCT01501838
First received: June 16, 2011
Last updated: December 26, 2011
Last verified: December 2011
History of Changes
  Purpose

The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires.


Condition
Death

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hospital Italiano de Buenos Aires:

Primary Outcome Measures:
  • Pulmonary hypertension prevalence and incidence [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    The main goal is to describe Pulmonary hypertension prevalence and incidence in our community as well as depict its risk factors, symptoms, prognosis and treatment response.


Secondary Outcome Measures:
  • Mortality rate [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 100000
Study Start Date: December 2010
Detailed Description:

The Institutional Registry of Pulmonary Hypertension includes patients prospectively with incident pulmonary hypertension, and excludes type II Pulmonary Hypertension. It also includes prevalent cases from our HMO who had diagnosis prior the beginning of the registry.

  Eligibility

Ages Eligible for Study:   17 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adults 17 yo or older, Any type of Pulmonary Hypertension except type II

Criteria

Inclusion Criteria:

  • More 17
  • Pulmonary Hypertension
  • Systolic Pulmonary Pressure >40 mmhg measured in a doppler echocardiogram,
  • Systolic artery pressure <25 in a pulmonary angiography

Exclusion Criteria:

  • Non accept to participate
  • Pulmonary Hypertension type II (Left cardiac disease)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01501838

Contacts
Contact: Diego H Giunta, MD 00541149590200 ext 4419 diego.giunta@hospitalitaliano.org.ar
Contact: Cristina M Elizondo, MD 00541149590200 ext 4525 cristina.elizondo@hospitalitaliano.org.ar

Locations
Argentina
Hospital Italiano de Buenos Aires Recruiting
Buenos Aires, Argentina, 1181
Contact: Diego h Giunta, MD     000541149590200 ext 4419     diego.giunta@hiba.org.ar    
Contact: Cristina M Elizondo, MD     00541149590200 ext 4419     cristina.elizondo@hiba.org.ar    
Sub-Investigator: Cristina M Elizondo, MD            
Sub-Investigator: Graciela Svetliza, MD            
Sub-Investigator: Norberto Vulcano, MD            
Sponsors and Collaborators
Hospital Italiano de Buenos Aires
Investigators
Principal Investigator: Diego H Giunta, MD Hospital Italiano de Buenos Aires
  More Information

No publications provided

Responsible Party: Diego Giunta, Principal Investigator, Hospital Italiano de Buenos Aires
ClinicalTrials.gov Identifier: NCT01501838     History of Changes
Other Study ID Numbers: 1487
Study First Received: June 16, 2011
Last Updated: December 26, 2011
Health Authority: Argentina: Human Research Bioethics Committee

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
 Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 21, 2013